JP2021500409A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500409A5 JP2021500409A5 JP2020543474A JP2020543474A JP2021500409A5 JP 2021500409 A5 JP2021500409 A5 JP 2021500409A5 JP 2020543474 A JP2020543474 A JP 2020543474A JP 2020543474 A JP2020543474 A JP 2020543474A JP 2021500409 A5 JP2021500409 A5 JP 2021500409A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- combination
- use according
- splice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 87
- 101000666295 Homo sapiens X-box-binding protein 1 Proteins 0.000 claims description 50
- 102100038151 X-box-binding protein 1 Human genes 0.000 claims description 50
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 102100035721 Syndecan-1 Human genes 0.000 claims description 21
- 102100032831 Protein ITPRID2 Human genes 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims description 18
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 15
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 15
- 206010006187 Breast cancer Diseases 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 230000003308 immunostimulating effect Effects 0.000 claims description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000005865 ionizing radiation Effects 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 108700002563 poly ICLC Proteins 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000013066 combination product Substances 0.000 claims 2
- 229940127555 combination product Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 37
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023138078A JP2023155331A (ja) | 2017-10-24 | 2023-08-28 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
| JP2025138218A JP2025164866A (ja) | 2017-10-24 | 2025-08-21 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762576404P | 2017-10-24 | 2017-10-24 | |
| US62/576,404 | 2017-10-24 | ||
| PCT/US2018/057039 WO2019083962A1 (en) | 2017-10-24 | 2018-10-23 | PEPTIDE AND PEMBROLIZUMAB VACCINES FOR THE TREATMENT OF BREAST CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138078A Division JP2023155331A (ja) | 2017-10-24 | 2023-08-28 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500409A JP2021500409A (ja) | 2021-01-07 |
| JP2021500409A5 true JP2021500409A5 (enExample) | 2021-12-09 |
Family
ID=64650461
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543474A Pending JP2021500409A (ja) | 2017-10-24 | 2018-10-23 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
| JP2023138078A Pending JP2023155331A (ja) | 2017-10-24 | 2023-08-28 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
| JP2025138218A Pending JP2025164866A (ja) | 2017-10-24 | 2025-08-21 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023138078A Pending JP2023155331A (ja) | 2017-10-24 | 2023-08-28 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
| JP2025138218A Pending JP2025164866A (ja) | 2017-10-24 | 2025-08-21 | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12059463B2 (enExample) |
| EP (1) | EP3700575A1 (enExample) |
| JP (3) | JP2021500409A (enExample) |
| CN (1) | CN111465411A (enExample) |
| AU (2) | AU2018353984A1 (enExample) |
| CA (1) | CA3079422A1 (enExample) |
| WO (1) | WO2019083962A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102256001B1 (ko) * | 2019-07-02 | 2021-05-26 | 주식회사 엔에이백신연구소 | 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물 |
| AU2020299074B2 (en) | 2019-07-02 | 2024-02-22 | Na Vaccine Institute | Novel ribonucleic acid and pharmaceutical composition based on the same |
| EP4149483A4 (en) * | 2020-05-15 | 2024-09-11 | Fred Hutchinson Cancer Center | COMPOSITIONS AND METHODS FOR IMPROVING CANCER IMMUNOTHERAPY |
| CN114231628A (zh) * | 2021-12-03 | 2022-03-25 | 无锡臻和生物科技有限公司 | 预测胃肠肿瘤免疫检查点抑制剂疗效的标志物组合及其应用 |
| WO2025101688A1 (en) * | 2023-11-08 | 2025-05-15 | Mary Hitchcock Memorial Hospital For Itself And On Behalf Of Dartmouth-Hitchcock Clinic (Collectively Doing Business As Dartmouth-Hitchcock) | Combination therapy using tetrathiomolybdate |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1359937A4 (en) | 2001-02-14 | 2004-07-28 | Genzyme Corp | MODIFIED PEPTIDE LIGANDS |
| ES2402184T5 (es) | 2003-12-01 | 2016-10-25 | Sloan-Kettering Institute For Cancer Research | Análogos de péptidos de unión a HLA sintéticos y sus usos |
| CA2726804C (en) * | 2008-06-02 | 2021-12-28 | Dana-Farber Cancer Institute, Inc. | Xbp1, cd138, and cs1 peptides |
| JP6374392B2 (ja) * | 2012-11-05 | 2018-08-15 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法 |
-
2018
- 2018-10-23 US US16/758,682 patent/US12059463B2/en active Active
- 2018-10-23 EP EP18815369.6A patent/EP3700575A1/en not_active Withdrawn
- 2018-10-23 AU AU2018353984A patent/AU2018353984A1/en not_active Abandoned
- 2018-10-23 WO PCT/US2018/057039 patent/WO2019083962A1/en not_active Ceased
- 2018-10-23 CA CA3079422A patent/CA3079422A1/en active Pending
- 2018-10-23 JP JP2020543474A patent/JP2021500409A/ja active Pending
- 2018-10-23 CN CN201880080350.XA patent/CN111465411A/zh active Pending
-
2023
- 2023-08-28 JP JP2023138078A patent/JP2023155331A/ja active Pending
-
2024
- 2024-07-03 US US18/763,857 patent/US20250018031A1/en active Pending
- 2024-11-07 AU AU2024259780A patent/AU2024259780A1/en not_active Abandoned
-
2025
- 2025-08-21 JP JP2025138218A patent/JP2025164866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11904002B2 (en) | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines | |
| JP7304629B2 (ja) | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| ES3064827T3 (en) | Dendritic cell immunotherapy | |
| JP2025508786A5 (enExample) | ||
| JP7030156B2 (ja) | 改善されたインターフェロン療法 | |
| US20240342211A1 (en) | Short-term activated dc1s and methods for their production and use | |
| JP2019527676A5 (enExample) | ||
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| JP2022501332A5 (enExample) | ||
| CN111225673A (zh) | 亚德阿霉素组合治疗及方法 | |
| JP2025507571A5 (enExample) | ||
| Corfield et al. | Understanding the role of new systemic agents in the treatment of prostate cancer | |
| CN113440533B (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| US20230173049A1 (en) | Fusion proteins and methods of use thereof | |
| JP6649953B2 (ja) | 免疫療法による治療および組成物 | |
| WO2007060918A1 (ja) | 新規なメモリーｃｔｌ誘導増強剤 | |
| WO2024238486A2 (en) | Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer | |
| KR20230115351A (ko) | Hank 세툭시맙 조합 및 방법 | |
| CN115715803A (zh) | 溶瘤病毒和免疫相关药物在协同抑制实体瘤中的应用 | |
| JP2016193903A5 (enExample) | ||
| Mahmoud et al. | Metastatic renal cell carcinoma presenting as painful chewing successfully treated with combined nivolumab and sunitinib | |
| CN116870150A (zh) | Pnu112455a抑制剂和pd-1抗体联用在制备肝细胞癌免疫治疗药物中的应用 | |
| WO2022236963A1 (zh) | 聚普瑞锌在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| JPS6391332A (ja) | 抗腫瘍剤 |